key: cord-0878192-9x311mnh authors: Eryavuz Onmaz, Duygu; Abusoglu, Sedat; Onmaz, Mustafa; Humeyra Yerlikaya, Fatma; Unlu, Ali title: Development and validation of a sensitive, fast and simple LC-MS / MS method for the quantitation of favipiravir in human serum date: 2021-05-20 journal: J Chromatogr B Analyt Technol Biomed Life Sci DOI: 10.1016/j.jchromb.2021.122768 sha: 626078d7cce0d0f2d23f275f680a5463951e3a4c doc_id: 878192 cord_uid: 9x311mnh Favipiravir is a broad-spectrum inhibitor of viral RNA polymerase. It is currently used as a possible treatment for coronavirus disease 2019 (COVID-19). Pre-clinical or clinical trials of favipiravir require robust, sensitive, and accurate bioanalytical methods for quantitation of favipiravir levels. Recently, several studies have been reported about developing a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for measuring favipiravir levels. However, these methods were validated predominantly for plasma samples, electrospray ionization was operated only in negative or positive mode, and clinical application of these methods has not been applied for patients with COVID-19. This study aimed was to develop a validated LC-MS/MS method for the measurement of favipiravir levels in positive and negative electrospray ionization mode and to perform a pilot study in patients with COVID-19 receiving favipiravir to demonstrate the applicability of this method in biological samples. Simple protein precipitation was used for the extraction of favipiravir from the desired matrix. Favipiravir levels were quantitated using MS / MS with an electrospray ionization source in positive and negative multiple reaction monitoring (MRM) mode. The chromatographic detection was performed on a reverse-phase Phenomenex C18 column (50 mm x 4.6 mm, 5µm, 100 Å) with gradient elution using 0.1% formic acid in water and 0.1% formic acid in methanol as mobile phase. The method was linear over the concentration ranges of 0.048–50 µg/mL (in negative ionization mode) and 0.062-50 µg/mL (in positive ionization mode) with a correlation coefficient (r2) better than 0.998. The total run time was 3.5 min. The intra-assay and inter-assay %CV values were less than 7.2% and 8.0%, respectively. A simple, rapid and robust LC-MS / MS method was developed for the measurement of favipiravir and validation studies were performed. The validated method was successfully applied for drug level measurement in COVID-19 patients receiving favipiravir. Since December 2019, a new coronavirus (severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)) infection has spread rapidly, causing respiratory disease coronavirus disease 2019 (COVID- 19) , threatening the health of many people [1] . The disease was first reported in Wuhan, China, but has now evolved into a pandemic, and it is currently known >156 million people globally in over 219 countries have been infected and more than 3.2 million people have died of COVID-19 [2, 3] . At the end of March 2021, the reported hospitalization rates were 12.5% for over 65 years old, 9.5% for the aged 50-64, and the case fatality rate was estimated to be around 2.3% globally [4, 5] . The symptoms of COVID-19 can range from asymptomatic to acute respiratory distress syndrome or multi-organ dysfunction. The common clinical symptoms in patients are fever, cough, fatigue, joint pain, sore throat, and shortness of breath [6] . COVID-19 has become a global health emergency, with the lack of effective medical treatment and incipient vaccines [7] . Various treatments and prophylactic approaches are used to treat or prevent COVID-19, including oxygen therapy, ventilation support, convalescent plasma therapy, cell therapy, vaccines and drugs [8] . To date, global coronavirus vaccine research and development has covered the categories of live virus and inactivated vaccines, subunit vaccines, vector vaccines, nucleic acid vaccines (mRNA vaccines and DNA vaccines) [9] . Some of the authorized vaccines available for COVID-19 include Comirnaty (BioNTech, Germany, mRNA- Oxford, 70% efficacy), Covaxin (Bharat Biotech, India, inactivated vaccine, 81% efficacy) [10] . Antimalarial agents (hydroxychloroquine, chloroquine), nucleotide analogues (remdesivir), nucleoside analogues (favipiravir, ribavirin), protease inhibitors (lopinavir, ritonavir), immunotherapy agents (tocilizumab, sarilumab), corticosteroids (dexamethasone, methylprednisolone), non-steroidal anti-inflammatory agents (naproxen, aspirin), antibiotics (azithromycin, teicoplanin), anticoagulants (nafamostat) are commonly registered drugs in COVID-19 clinical trials [8, [11] [12] [13] . One of the agents investigated for the COVID-19 treatment is favipiravir (Avigan™), (T-705), (6-fluoro-3-hydroxy-2-pyrazinecarboxamide), an oral pyrazinecarboxamide derivative [14] . Favipiravir, a purine analog and a potent RNA-dependent RNA polymerase inhibitor [15] . It is effective against a large number of RNA viruses including influenza, arena-, bunya-, flavi-and filo-, noroviruses, West Nile virus, yellow fever virus, Ebola virus, Lassa virus [16] . Favipiravir is approved for influenza treatment and is currently considered in the treatment of COVID-19 [15] . It has a well-established safety profile and any serious adverse events related to favipiravir have not been reported. The most common side effects reported in clinical trials are increased serum uric acid levels, gastrointestinal side effects, increased transaminase levels and decreased neutrophil count [17] . Favipiravir reaches maximum blood concentration 2 hours after oral administration and has a short elimination half-life of 2-5.5 hours. It is 54% bound to plasma proteins (albumin and α1-acid glycoprotein) [18] . Favipiravir is a prodrug that is metabolized to its active metabolite, favipiravir-ribofuranosyl-5'-triphosphate, by phosphoribosylation in the cell. It has been reported that the human hypoxanthine-guanine phosphoribosyltransferase enzyme may play a role in this activation process [19] . Favipiravir is also metabolized in the liver to its inactive metabolite T-705M1 mainly via aldehyde oxidase, partly xanthine oxidase. Favipiravir is extensively metabolized and only 1% is excreted a parent drug via the urinary. In COVID-19, a multi-drug regimen is applied to patients, especially if there are comorbidities. Therefore, the risk of drug-drug interaction increases. Studies have reported that coadministration of acetaminophen and favipiravir caused an increase in levels of acetaminophen and acetaminophen glucuronide by approximately 20% and 30%, respectively. Potential drug interactions should be carefully monitored when agents that inhibit aldehyde oxidase (raloxifene, tamoxifen, estradiol, cimetidine, felodipine, amlodipine, verapamil) or metabolize via aldehyde oxidase (citalopram, zaleplon, famciclovir, sulindac) are used with favipiravir [18, 20] . Therefore, monitoring of favipiravir levels is extremely important for an effective and safe treatment. Until now, several LC-MS/MS [21] [22] [23] [24] [25] [26] and high-performance liquid chromatography methods [27] [28] [29] have been reported for the quantitation of favipiravir levels. These HPLC methods have low sensitivity, require long analysis time and larger sample volumes. LC-MS/MS is the gold standard method for therapeutic drug level monitoring [30] . However, validation studies are lacking for most of these methods [21] [22] [23] . Recently, several studies have been reported about developing a validated LC-MS/MS method for measuring favipiravir levels [24] [25] [26] . However, these methods were validated for plasma samples, electrospray ionization was operated only in negative or positive mode, and clinical application of these methods has not been applied for patients with COVID-19. Therefore, we conducted validation studies by developing LC-MS/MS method in both negative and positive electrospray ionization mode for the measurement of favipiravir levels. The validated bioanalytical methods were successfully applied for drug level measurement in COVID-19 patients receiving favipiravir. The method developed differently from the others was validated for serum samples and favipiravir levels were compared in serum and plasma samples taken from COVID-19 patients. Atorvastatin, favipiravir, acetonitrile, methanol, HPLC grade water, formic acid were obtained from Sigma Aldrich (St. Louis, MO, USA). Individual stock solutions (1 mg / mL favipiravir and 0.5 mg / mL atorvastatin) were prepared separately in methanol for the preparation of quality control samples and calibration standards. The sample preparation procedure of favipiravir was briefly, 100 μL internal standard (1250 ng/mL atorvastatin) and 600 μL acetonitrile were added to 250 μL sample or standard solution and vortexed for 30 seconds. Afterward, the reaction mixture was centrifuged at 2000×g for 10 minutes and 30 μL of supernatant was injected into the LC-MS/MS system. Shimadzu HPLC system (Kyoto, Japan) consisted of a pump (LC-20 AD), an automatic sampler (SIL-20 AC HT) and a unit for online degasser (DGU-20A3). Mass spectrometric analyses were performed using an API 3200 triple quadrupole mass spectrometer (Applied Biosystems/MDS Sciex) equipped with an electrospray ion source (ESI) operating in positive and negative mode. Chromatographic separation was performed using a Phenomenex C18 HPLC column (50 mm The method validation study was performed according to Clinical and Laboratory Standards The Food and Drug Administration (FDA) guidelines [31, 32] . Linearity, precision, recovery, matrix effect, stability, carry-over, selectivity, and specificity parameters were evaluated in this study. Each calibration curve was generated by analysis of two replicates of one blank sample, one zero sample (blank with internal standard added), and eleven non-zero standards. The calibration curves were generated by plotting the peak area ratios of analyte / internal standard versus nominal analyte concentrations. The calibration curve was established using the following criteria: (1) the mean value should be within ±15% of the theoretical value, except at the LLOQ, where it should not deviate by more than ±20%; (2) the correlation coefficients (r 2 ) of all calibration curves should be more than 0.980. The precision and accuracy were evaluated using quality control samples prepared at LLOQ, low, medium 1, medium 2, and high QC levels of favipiravir. The inter-day precision studies were performed analyzing four replicates per level at the LLOQ, low, medium 1, medium 2 and high QC samples for 5 consecutive days. The intra-day precision study was carried out by analyzing a total of 40 replicates, 20 in the morning and 20 in the afternoon for each level. For quality control samples at low level, medium1, medium 2 level, and high level, the intra-and inter-assay precision should be equal to or less than 15% and the intra-and inter-assay accuracy should be between 85% and 115%. For LLOQ samples, the intra-and inter-assay precision should be no more than 20% and the intra-and inter-assay accuracy should be from 80% to 120%. Matrix effects and recovery were determined using 6 different negative matrix sources at low, medium and high concentrations (n = 3) and were considered acceptable within ±25% of the target area at the respective concentration. According to the CLSI guideline, the recovery values should be between 85% and 115% at the points where the concentration level is more than 3 times the LLOQ, while it should be between 80% and 120% at low concentration levels. Percent matrix bias (100-%ME) should be less than 15%. In the carry-over study, low and high level analyte spiked remnant blank serum samples were sequentially analyzed For the acceptability of this study, the calculated carry-over results should be less than 3 × SD low-low results. The stability of favipiravir in serum samples following four freeze -thaw cycles (room temperature to −20 ° C to room temperature), long-term sample storage (−20 ° C for 45 days) was evaluated by determining at LQC, MQC and HQC concentrations (n = 3). The acceptability criteria was that all calculated bias% values were less than 15% . The selectivity was evaluated by comparing the chromatogram of six different blank serum samples with that of favipiravir and internal standard spiked serum samples. The acceptability criteria was that the blank and zero calibrators were free of interference in the retention times of the favipiravir and internal standard [31, 32] . The validated LC-MS/MS method was applied to randomized remnant serum samples from patients with COVID-19 receiving favipiravir (n=55). Analysis was performed in accordance with the Declaration of Helsinki and ethical approval was obtained from the Selcuk University local Ethics Committee (Number: 2021/151, Date: 10/03/2021). The patients were administered 1,600 mg of FPV twice daily on day 1, followed by 600 mg twice daily from day 2 to day 5. In less than 12 hours from the last dosage, blood samples were taken immediately and transferred to the laboratory and serum samples were obtained from collection tubes without gel additive by centrifugation at 2000×g for 10 min, plasma samples were obtained from EDTA containing tubes by centrifugation at 2000×g at 4ºC for 10 min. Serum and plasma samples were separated and stored at 80 • C and analyzed within two weeks. 30 samples were used for the comparison of the different matrix (serum and plasma) in a total of 55 patient samples. Statistical analysis was performed using EP Evaluator Release 8 version (Data Innovations, South Burlington, VT), Excel (2010) programs. Data analysis was processed by SCIEX Analyst ® 1.6.2 Software. Analyte concentrations were calculated using the internal standard method. The standard curves were generated from the peak area ratios of analyte / internal standard and the nominal analyte concentrations using a linear regression analysis y = a + bx with a weighting factor (1 / x 2 ). The limit of blank (LOB) value was calculated by analysis of 20 replicates of the blank serum sample and the following formula: LOB = meanblank + 1.65 SD blank . The LOD value was calculated by the following formula after the analysis of 20 replicates of low-level analyte spiked serum samples: LOD = LOB + 1.645 (SD low concentration sample ). The recovery results are calculated as the average of "measured value/expected value" ratio (%). The matrix effect was calculated with the following formula: (ME% = (mean post-extracted peak area / mean unextracted peak area) × 100). The bias% value was calculated as: Bias%= . The %CV values were calculated with the following ( standard deviation mean ) × 100 Different pre-treatment steps such as protein precipitation, evaporation, liquid-liquid extraction (LLE) were tried to extract favipiravir from the biological matrix. Peak intensities and shapes were satisfactory in these methods, however protein precipitation was preferred due to its simple, fast, and economical nature. Various organic solvents such as acetonitrile, ethanol, and methanol were used for protein precipitation, the best peak shape and lowest matrix effect were achieved with acetonitrile. Favipiravir is used in high dose (2x8 loading on the first day, 2x3 maintenance dose on the other 4 days) in the treatment of COVID-19. The current method developed based on protein precipitation has sufficient sensitivity (LLOQ) and selectivity for quantitation of favipiravir in the patient population. Therefore, only protein precipitation was preferred due to the advantages mentioned above. Different mobile phases including methanol-water, acetonitrile-water were evaluated by isocratic or gradient elution to improve chromatographic separation, and peak shape. To increase the ionization, additives such as formic acid, ammonium formate, acetic acid were Linearity study was performed according to CLSI EP06-A protocol [31] . LLOQ has been determined in according to FDA guidelines [32] . FDA guidelines recommend analyzing at least 5 replicates in at least 3 different independent runes for each of the five QC (LLOQ, low, medium 1, medium 2, and high QC) levels in the precision study. The inter-day precision studies were performed analyzing four replicates per level at the LLOQ, low, medium 1, medium 2, and high QC samples (Table 1) for 5 consecutive days. The intra-day precision study was carried out by analyzing a total of 40 replicates, 20 in the morning and 20 in the afternoon for each level [32] . The results were summarized in Table 1 . The recovery study was performed according to the CLSI EP6-A protocol [31] . The three different sample sets consisting of low, medium and high-level analytes selected throughout the calibration curve were prepared by spiking into at least 6 different remnant blank serum samples ( Table 2 ). The recovery study results were calculated as the average "measured value/expected value" ratio (%). The matrix effect is determined by two common methods. These are postcolumn infusion and post-extraction spike methods. We performed the matrix effect study with the second method described by Chambers et al [34] . In this method, the response of the analyte in neat solution is compared with the response of the spiked analyte to the pre-treated blank matrix. Accordingly, the analyte response in a mixture of water: acetonitrile (50:50, v/v%) containing three different levels of analyte selected along the calibration curve was compared with the analyte response obtained as a result of spiking to the pre-treated remnant blank serum sample, and the matrix effect was calculated with the following formula: (ME% = (mean postextracted peak area / mean un-extracted peak area) × 100). The results were expressed in Table 2 . The stability study was carried out according to the CLSI EP25-A protocol [31] . The stability study was performed using remnant blank serum samples containing spiked analyte at three different concentration levels, low, medium and high, selected along the calibration curve (Table 3 ). In this context, firstly, the effect of the freeze-thaw process on sample stability was investigated. After determining the concentration of analyte on the day of preparation for each level, the remaining 1000 microliters of the sample were aliquoted. The concentration of favipiravir was measured in each thaw cycle by performing 4 freeze-thaw cycles (room temperature to −20 ° C to room temperature). Secondly, after measuring favipiravir levels on the preparation day, three samples containing 250 μL of each sample were stored at -20 °C. The results were expressed in Table 3 . The carryover study was performed according to the CLSI EP10-A protocol [31] . In this study, low and high level analyte spiked remnant blank serum samples were sequentially analyzed according to the order in the EP Evaluator Release program. The mean of high-low results, mean of low-low results, 3 × SD low-low results and carry-over values were calculated through the program. In the program, the carry-over value was calculated with the following formula: Carry-over = (mean of high-low results) -(mean of low-low results). For the acceptability of this study, the calculated carry-over results should be less than 3 × SD low-low results. In our study, the mean of high-low results were calculated as 0.110 µg/mL in positive mode and 0.099 µg/mL in negative mode. The mean of low-low results are calculated as 0.100 µg/mL in the method applied in positive mode and 0.088 µg/mL in the method applied in negative mode. Accordingly, the carry-over values were calculated as 0.010 µg/mL in the positive method and 0.011 µg/mL in the negative method, respectively. SD low-low results were calculated as 0.010 and 0.084 µg/mL, respectively. Therefore, the allowable carry-over values should be less than 0.030 and 0.252 µg/mL, respectively (less than 3 × SD low-low results). Therefore, our carry-over results were at acceptable levels in both methods. The selectivity and specificity studies were carried out in according to FDA guidelines [32] . In the selectivity study, the remnant blank serum sample was analyzed and no interfering peak was found in retention times corresponding to favipiravir and internal standard (atorvastatin) in the chromatogram of the blank. In addition, the internal standard response in the blank remnant serum did not exceed 5% of the response in the other calibration and working solutions. As part of the specificity study, an interference study was conducted with allopurinol according to CLSI EP7-A [31] . As part of the specificity study, an interference study was conducted with allopurinol. 0%, 25%, 50%, 75%, and 100% of the remnant spiked serum pool containing 2000 ng/mL allopurinol was added to the remnant serum sample spiked low, medium and high-level favipiravir. The results are expressed as bias% in Table 4 . 15.7 μg / mL) reported by Lou et al. [41] Serum favipiravir levels of patients with blood drawn on the 2nd and 5th days of treatment were below 7.2 μg/mL, while it was less than 2 μg/mL in the post-treatment group. Mass spectrometry was operated in negative ionization mode and positive ionization mode for measurement of serum favipiravir levels, and serum favipiravir levels were found consistent in both modes (p=0.795). In addition, plasma and serum favipiravir levels were largely similar when measured by the validated method for serum samples (p=0.912). The LC-MS/MS method was developed for the measurement of favipiravir and validation studies were performed. The validated method was successfully applied for drug level measurement in COVID-19 patients receiving favipiravir. Simple sample preparation, costeffectiveness, rapid quantification, satisfactory precision, accuracy and sensitivity are the main advantages of the method. The assay can be used for routine favipiravir therapeutic drug monitoring in clinical laboratories. However, the limitations of the study are the lack of a multiplexed drug method, the use of the surrogate internal standard, the measurement of favipiravir levels in a limited number of patients, and the fact that favipiravir levels were not measured for each patient on consecutive days. To elucidate the pharmacokinetic and pharmacodynamic characteristics of favipiravir in COVID-19 patients, further studies are required to measure drug blood levels in well-defined conditions and to investigate the relationship between adverse effects and blood drug levels in a larger population. The authors declare that they have no conflict of interest relevant to the content of this manuscript. Characteristics of SARS-CoV-2 and COVID-19 Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence Coronavirus disease 2019, Cases&Data, COVID-NET Laboratory -confirmed COVID-19 hospitalizations COVID-19, SARS and MERS: are they closely related? COVID-19: Specific and Non-Specific Clinical Manifestations and Symptoms: The Current State of Knowledge CNBP Binds and Unfolds In Vitro G-Quadruplexes Formed in the SARS-CoV-2 Positive and Negative Genome Strands Review of registered clinical trials for the treatment of COVID-19 DNA vaccines against COVID-19: Perspectives and challenges The COVID-19 Vaccines: Recent Development, Challenges and Prospects The trinity of COVID-19: immunity, inflammation and intervention Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities A narrative review for emergency providers Favipiravir and COVID-19: A Simplified Summary Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study Candidate drugs against SARS-CoV-2 and COVID-19 Favipiravir Use in COVID-19: Analysis of Suspected Adverse Drug Events Reported in the WHO Database Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase Uric Acid Elevation by Favipiravir, an Antiviral Drug Clinical Regimens of Favipiravir Inhibit Zika Virus Replication in the Hollow-Fiber Infection Model Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted Fate of new three anti-influenza drugs and one prodrug in the water environment Development of a highly sensitive bioanalytical assay for the quantification of favipiravir Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC-MS/MS method in human serum A novel, rapid and simple UPLC MS/MS method for quantification of favipiravir in human plasma: Application to a bioequivalence study HPLC-UV method for quantification of favipiravir in pharmaceutical formulations A kind of Favipiravir has the HPLC assay method of related substance HPLC method for measuring related substances in Favipiravir CLSI document C62-A. Clinical and Laboratory Standards Institute, Liquid Chromatography-Mass Spectrometry Methods; Approved Guidelines Bionanalytical Method Validation, US Department of Health and Human Services/Food and Drug Administration Centre for Drug Evaluation and Research (CDER)/Centre for Veterinary Medicine Method validation: the detection limit experiment Systematic and comprehensive strategy for reducing matrix effects in LC/MS/MS analyses Detection and quantification of Covid-19 antiviral drugs in biological fluids and tissues Favipiravir: A new and emerging antiviral option in COVID-19 Favipiravir in Therapy of Viral Infections Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID-19 Package insert Avigan Tablet 200 mg (English translation) by Toyama Chemical Co., Ltd Report on the Deliberation Results Avigan Tablet 200 mg by Pharmaceuticals and Medical Devices Agency (PMDA) Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro Writing-Original draft preparation. Mustafa Onmaz: Conceptualization, Methodology, Data curation, Validation. Fatma Humeyra Yerlikaya: Conceptualization, Methodology, Writing-Reviewing, Visualization. Ali Unlu: Supervision, Software, Writing-Original draft preparation LLOQ: lower limit of quantification; LQC: low QC; MQC1: medium 1 QC; MQC2: medium 2 QC HQC: high QC Table 1. The intra-and inter-day precision study results of favipiravir. Intra-day(Positive mode) Inter QC Concentration(μg/mL) Mean(μg/mL) Accuracy% Precision(%CV) Mean(μg/mL) Positive mode Concentration(μg/mL ) Frozen (-20 °C) for 45 day Freeze-thaw stability The interference study results of favipiravir (bias%). Positive mode Concentration(μg/mL) The authors would like to thank the Selcuk University for this study. ☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☒The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:The authors declare that they have no conflict of interest relevant to the content of this manuscript.